Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Liao, Kang Ling ^a   Bai, Xue Feng ^b   Friedman, Avner ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; INTERLEUKIN 35; INTERLEUKIN 35 INHIBITOR; OXYGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, MOUSE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; MATHEMATICAL MODEL; REGULATORY T LYMPHOCYTE; SIMULATION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; INTERLEUKINS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84910062923     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110126     Document Type: Article

References (92)

1. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, et al. (2013) Tumor-derived il-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immuno 190:2415-2423.
2. Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, et al. (2013) Assessing the role of il-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 6:1806-1816.
3. Long J, Zhang X, Wena M, Kong Q, Lv Z, et al. (2013) Il-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochemical and Biophysical Research Communications 430:364-369.
4. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory t cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761.
5. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, et al. (2005) The expression of the regulatory t cell-specific forkhead box transcription factor foxp3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326-8331.
6. + t cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clinical Cancer Research 13:4345-4354.
7. Eller K, Wolf D, Huber JM, Metz M, Mayer G, et al. (2011) Il-9 production by regulatory t cells recruits mast cells that are essential for regulatory t cellonduced immune suppression. J Immunology 186:83-91.
8. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. (2007) The inhibitory cytokine il-35 contributes to regulatory t-cell function. Nature 450:566-569.
9. Collison LW, Vignali DAA (2008) Interleukin-35: odd one out or part of the family? Immunol Rev 226:248-262.
10. Vignali DAA, Collison LW, Workman CJ (2008) How regulatory t cells work. Nat Rev Immunol 8:523-532.
11. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, et al. (2010) Regulation of antitumor immune responses by the il-12 family cytokines, il-12, il-23, and il-27. Clinical and Developmental immunology 14:832454.
12. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DAA (2011) Human regulatory t cells require interleukin-35 to mediate suppression and infectious tolerance. J Immunol 186:6661-6666.
13. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, et al. (2012) The composition and signaling of the il-35 receptor are unconventional. Nature immunology 13:290-299.
14. Vignali DAA, Kuchroo VK (2012) Il-12 family cytokines: immunological playmakers. Nature immunology 13:722-728.
15. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, et al. (2010) Il-35-mediated induction of a potent regulatory t cell population. Nat Immunol 11:1093-1101.
16. Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, et al. (2011) Identification of epstein-barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 17:6272-6286.
17. Larousserie F, Bardel E, Pflanz S, Arnulf B, Lome-Maldonado C, et al. (2005) Analysis of interleukin-27 (ebi3/p28) expression in epstein-barr virus- and human t-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of ebi3 subunit by tumoral cells. Am J Pathol 166:1217-1228.
18. Niedobitek G, Päolt D, Teichmann M, Devergne O (2002) Frequent expression of the epstein-barr virus (ebv)-induced gene, ebi3, an il-12 p40-related cytokine, in hodgkin and reed-sternberg cells. J Pathol 198:310-316.
19. Gabrilovich DI, Rosenberg SO, Bronte V (2012) Coordinated regulation of myeloid cells by tumors. Nat Rev Immunol 12:253-268.
20. Yang WC, Ma G, Chen SH, Pan PY (2013) Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol 5:207-209.
21. Kendall M (1998) Dying to live: How our bodies fight disease. Cambridge University.
22. Szomolay B, Eubank TD, Roberts RD, Marsh CB, Friedman A (2012) Modeling the inhibition of breast cancer growth by gm-csf. J Theoret Biol 303:141-151.
23. Lewis JS, Lee JA, Underwood JCE, Harris AL, Lewis CE (1999) Macrophage responses to hypoxia: relevance to disease mechanisms. J Leuk Biol 66:889-900.
24. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677-686.
25. Owen MR, Byrne HM, Lewis CE (2004) Mathematical modeling of the use of macrophages as vehicles for drug delivery to hypoxic tumor sites. J Theore Biol 226:377-391.
26. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct m2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. European J of Cancer 42:717-727.
27. Morishima N, Mizoguchi I, Okumura M, Chiba Y, Xu M, et al. (2010) A pivotal role for interleukin-27 in cd8+ t cell functions and generation of cytotoxic t lymphocytes. J Biomedicine and Biotechnology: doi:10.1155/2010/605483.
28. Baek HJ, Kim SS, da Silva FM, Volpe EA, Evans S, et al. (2006) Inactivation of tgf-beta signaling in lung cancer results in increased cdk4 activity that can be rescued by elf. Biochem Biophys Res Commun 11:1150-1157.
29. Colombo MP, Piconese S (2007) Regulatory t-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nature Reviews Cancer 7:880-887.
30. Danforth DNJ, Sgagias MK (1996) Tumor necrosis factor alpha enhances secretion of transforming growth factor beta2 in mcf-7 breast cancer cells. Clin Cancer Res 2:827-835.
31. Kretzschmar M (2000) Transforming growth factor-beta and brest cancer: transforming growth factor-beta/smad signaling defects and cancer. Breast Cancer Res 2:107-115.
32. Massagué J (1998) Tgf-beta signal transduction. Annu Rev Biochem 67:753-791.
33. Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6:613-625.
34. Robertson-Tessi M, El-Kareh A, Goriely A (2011) A mathematical model of tumor-immune interactions. Journal of Theoretical Biology 10:294-273.
35. Truty MJ, Urrutia R (2007) Basics of tgf-beta and pancreatic cancer. Pancreatology 7:423-435.
36. + regulatory t cells. J Mol Cell Biol 4:29-37.
37. + regulatory t cells is not essential for suppression of intestinal inflammation. Eur J Immunol 35:2886-2895.
38. Lo WC, Arsenescu RI, Friedman A (2013) Mathematical model of the roles of t cells in inflammatory bowel disease. Bull Math Biol 75:1417-1433.
39. Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, et al. (2011) Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of mcp-1. PLoS ONE 11:e18534.
40. Kross KW, Heimdal JH, Olsnes C, Olofson J, Aarstad HJ (2007) Tumorassociated macrophages secrete il-6 and mcp-1 in head and neck squamous cell carcinoma tissue. Acta Otolaryngol 127:532-539.
41. Robertson MJ, Ritz J (1996) Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1:88-97.
42. + t cells in tumor immunity. ISRN Immunology 2011: doi:10.5402/2011/497397.
43. Wagner H, Kronke M, Solbach W, Scheurich P, Rollinghoff M, et al. (1982) Murine t cell subsets and interleukins: relationships between cytotoxic t cells, helper t cells and accessory cells. Clin Haematol 11:607-630.
44. + t cell proliferation without modulating the cytokine response. Int Immunol 15:1495-1504.
45. + t cells. BMC Immunol 17: doi: 10.1186/1471-2172-14-30.
46. Thomas DA, Massagué J (2005) Tgf-β directly targets cytotoxic t cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380.
47. Eubank TD, Roberts RD, Khan M, Curry JM, Nuovo GJ, et al. (2009) Granulocyte macrophage colony-stimulating factor inhibits breats growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res 69:2133-2140.
48. Lin Y, Huang Y, Lu Z, Luo C, Shi Y, et al. (2012) Decreased plasma il-35 levels are related to the left ventricular ejection fraction in coronary artery diseases. PLoS ONE 7:e52490.
49. Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) A methodology for performing global uncertaintly and sensitivity analysis in systems biology. J Theor Biol 254:178-196.
50. Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, et al. (2014) Il-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: Evidence for a role as an autocrine growth factor. Cytokine: in press.
51. + regulatory t cells. J Immunol 177:896-904.
52. + and foxp3v precursor cells in the absence of interleukin 10. Nature immunology 8:931-941.
53. + t cells. PLoS ONE 5:e8706.
54. Schmitt EG, Haribhai D, Williams JB, Aggarwal P, Jia S, et al. (2012) Il-10 produced by induced regulatory t cells (itregs) controls colitis and pathogenic exitregs during immunotherapy. J Immunol 189:5638-5648.
55. Chen D, Roda JM, Marsh CB, Eubank TD, Friedman A (2012) Hypoxia inducible factors mediate the inhibtion of cancer by gm-csf: a mathematical model. Bull Math Biol 17:2752-2777.
56. Liao KL, Bai XF, Friedman A (2013) The role of cd200-cd200r in tumor immune evasion. J Theor Biol 328:65-76.
57. Plank MJ, Sleeman BD, Jones PF (2004) A mathematical model of tumor anglogenesis, regulated by vascular endothelial growth factor and the angiopoietins. J Theore Biol 229:435-454.
58. Day J, Friedman A, Schlesinger LS (2008) Modeling the immune rheostat of macrophages in the lung in response to infection. PNAS 106:11246-11251.
59. Freeman BJ, Roberts MS, Vogler CA, Nicholes A, Hofling AA, et al. (1999) Behavior and therapeutic efficacy of β-glucuronidase-positive mononuclear phagocytes in murine model of mucopolysaccharidosis type vii. Blood 94:2142-2150.
60. DiLeo MV, Kellum JA, Federspiel WJ (2009) A simple mathematical model of cytokine capture using a hemoadsorption device. Ann Biomed Eng 37:222-229.
61. Sánchez-Hernández C, Gutiérrez-Ortega A, Aguilar-León D, Hernández-Pando R, Gómez-Lim M, et al. (2010) In vivo activity of plant-based interleukin-12 in the lung of balb/c mouse. BMC Research Notes 3: doi: 10.1186/1756-0500-3-151.
62. Lee SM, Suen Y, Chang L, Bruner V, Qian J, et al. (1995) Decreased interleukin-12 (il-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of interferongamma, natural killer, and lyphokine-activated killer activity by il-12 in cord blood mononuclear cells. Blood 88:945-954.
63. Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, et al. (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5:9-16.
64. Todorović-Raković N, Ivanović V, Demajo M, Nešković-Konstantinovi Z, Nikolić-Vukosavljević D (2003) Elevated plasma levels of tgf-beta1 in patients with locally advanced breast cancer related to other clinical stages. Archive of Oncology 11:131-133.
65. Youn BS, Sen A, Behie LA, Girgis-Gabardo A, Hassell JA (2008) Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. Biotechnol Prog 22:801-810.
66. Breward CJW, Byrne HM, Lewis CE (2001) Modeling the interactions between tumor cells and a blood vessel in a microenvironment within a vascular tumor. European J Appl Math 12:529-556.
67. Qian B, Deng Y, Hong Im J, Muschel RJ, Zou Y, et al. (2009) A distinct macrophage population mediated metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4:e6563.
68. Vaupel P, Mayer A, Briest S, Höckel M (2003) Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 63:7634-7637.
69. Casciari JJ, Sotirchos SV, Sutherland RM (1988) Glucose diffusivity in multicellular tumor spheroids. Cancer Res 48:3905-3909.
70. Owen MR, Sherratt JA (1998) Pattern formation and spatiotemporal irregularity in a model for macrophage tumor interactions. J Theore Biol 189:63-80.
71. Oren H, Duman N, Abacioglu H, Ozkan H, Irken G (2001) Association between serum macrophage colony-stimulating factor levels and monocyte and thrombocyte counts in healthy, hypoxic, and septic term neonates. Pediatrics 108:329-332.
72. Utting JC, Flanagan AM, Brandao-Burch A, Orriss IR, Aenett TR (2010) Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochem Funct 28:374-380.
73. Tang S, Liu H, Chen G, Rao Q, Geng Y, et al. (2000) Internalization and halflife of membrane-bound macrophage colony-simulating factor. Chinese Sc Bull 45:1697-1703.
74. hifoxp3 regulatory t cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116:2423-2433.
75. Yates A, Callard R (2001) Cell death and the maintenance of immunological memory. Discret Contin Dyn S 1:43-59.
76. Kim Y, Friedman A (2010) Interaction of tumor with its micro-environment: a mathematical model. J Math Biol 72:1029-1068.
77. Marino S, Kirschner DE (2004) The human immune response to mycobacterium tuberculosis in lung and lymph node. J Theor Biol 227:463-486.
78. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN (2001) Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166:7556-7562.
79. Kim Y, Lawler S, Nowicki MO, Chiocca EA, Friedman A (2009) A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. J Theore Biol 260:359-371.
80. Kim Y, Wallace J, Li F, Ostrowski M, Friedman A (2010) Transfirmed epithelial cells and fibroblasts/myofibroblasts interaction in breast tumor: a mathematical model and experiments. J Math Biol 61:401-421.
81. Hengel RL, Jones BM, Kennedy MS, Hubbard MR, McDougal JS (1999) Markers of lymphocyte homing distinguish cd4 t cell subsets that turn over in response to hiv-1 infection in humans. J Immunol 163:3539-3548.
82. Sachsenberg N, Perelson AS, Yerly S, Schockmel GA, Leduc D, et al. (1998) Turnover of cd4+ and cd8+ t lymphocytes in hiv-1 infection as measured by ki-67 antigen. J Exp Med 187:1295-1303.
83. Sprent J, Basten A (1973) Circulating t and b lymphocytes of the mouse. ii. lifespan. Cell Immunol 7:40-59.
84. Wigginton JE, Kirschner D (2001) A model to predict cell-mediated immune regulatory mechanisms during human infection with mycobacterium tuberculosis. J Immunol 166:1951-1967.
85. Winslow GM, Roberts AD, Blackman MA, Woodland DL (2003) Persistence and turnover of antigen-specific cd4 t cells during chronic tuberculosis infection in the mouse. J Immunol 170:2046-2052.
86. Gabhann FM, Popel AS (2003) Model of competitive binding of vascular endothelial growth factor and placental growth factor to vegf receptors on endothelial cells. Am J Physiol Heart Circ Physiol 286:H153-H164.
87. Schugart RC, Friedman A, Zhao R, Sen CK (2008) Wound angiogenesis as a function of tissue oxygen tension: a mathematical model. PNAS 105:2628-2633.
88. Chaplain MAJ, Giles SM, Sleeman BD, Jarvis RJ (1995) Amathematical analysis of a model for tumour angiogenesis. J Math Biol 33:744-770.
89. Eubank TD, Roberts R, Galloway M, Wang Y, Cohn DE, et al. (2004) Gm-csf induces expression of soluble vegf receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity 21:831-842.
90. Chaplain MAJ (1995) The mathematical modeling of tumour angiogenesis and invasion. Acta Biotheoret 43:387-402.
91. Butterworth AE, Cater DB (1967) Effect of lysolecithin on oxygen uptake of tumor cells polymorphonuclear leucocytes lymphocytes and macrophages in vitro. Br J Cancer 21:373-389.
92. Chen Y, Cairns R, Papandreou I, Koong A, Denko NC (2009) Oxygen consumption can regulate the growth of tumors, a new perspective on the warburg effect. PLoS ONE 4:e7033.